Recent posts
View all
health-issue
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
https://ift.tt/EC0Dfb2 New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis from Sanofi - Avent…
Read more
health-issue
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
https://ift.tt/A0ToFrW from Sanofi - Aventis Groupe https://ift.tt/QMy8utp via IFTTT
Read more
health-issue
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
https://ift.tt/MkUtvnu New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis from …
Read more
health-issue
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
https://ift.tt/7IHisUh from Sanofi - Aventis Groupe https://ift.tt/z2ouJMf via IFTTT
Read more
health-issue
Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
https://ift.tt/5IzSWUl from Sanofi - Aventis Groupe https://ift.tt/2LMWYdk via IFTTT
Read more
health-issue
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
https://ift.tt/b4Tra1I from Sanofi - Aventis Groupe https://ift.tt/RyPeoAn via IFTTT
Read more
health-issue
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
https://ift.tt/n6MIarl Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation from Sanofi - Aventis Grou…
Read more